December 2, 2022 Uncategorized BetterLife To Present BETR-001 Preclinical Data at the 61ST Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Phoenix, Arizona Read More
September 27, 2022 Uncategorized BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives Read More
September 7, 2022 Uncategorized BetterLife and Collaborators to Submit Key Joint Research Publication Read More
August 24, 2022 Uncategorized BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic Effects Similar to That of LSD Without Hallucinogenic Side Effects Read More
July 6, 2022 Uncategorized BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies Read More
June 23, 2022 Uncategorized BetterLife To Participate at the H.C. Wainwright 1st Annual Mental Health Conference Read More
June 21, 2022 Uncategorized BetterLife To Present BETR-001 Preclinical Data at the Upcoming Federation of European Neuroscience Societies (FENS) Forum Read More
April 21, 2022 BetterLIfe Pharma PR BetterLife To Present BETR-001 Preclinical Data at the Upcoming Canadian Association for Neuroscience Conference Read More
April 6, 2022 BetterLIfe Pharma PR BetterLife’s BETR-001 Demonstrates BETR-001 Anti-depressant Activity in Preclinical Models of Depression Read More